02/28/08 - Luminex Molecular Diagnostics, a division of Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexing solutions, has signed a global sales and distribution agreement with Abbott's (NYSE: ABT) molecular diagnostics business. Under the terms of the agreement, Abbott will have exclusive rights to distribute Luminex's new xTAGTM Respiratory Viral Panel (RVP) worldwide outside the United States and semi-exclusive rights in the United States.
Based on Luminex's xMAP® multiplexing technology, xTAG RVP was created by Luminex Molecular Diagnostics, in partnership with a team of leading virologists and infectious disease specialists. In a matter of hours from a single patient sample, the test allows doctors to detect the presence or absence of several viruses and subtypes at once... Luminex's Press Release -
